新型抗肿瘤药物拓扑异构酶Ⅱ抑制剂沙尔威辛的临床前研究  

Preclinical study for anticancer drug salvicine,a new topoisomerase Ⅱ inhibitor

作　　者：罗志国[1] 冯奉仪[1] 

机构地区：[1]中国医学科学院中国协和医科大学肿瘤医院内科,北京100021

出　　处：《中国新药杂志》2005年第2期140-142,共3页Chinese Journal of New Drugs

摘　　要：抗肿瘤药物沙尔威辛是我国自主研制的一种新的非DNA嵌入型拓扑异构酶Ⅱ抑制剂,临床前研究表明,其具有显著的体内外抗肿瘤活性,独特的抗肿瘤多药耐药作用以及多种与抗肿瘤有关的其他作用,且耐受性良好。现就其化学结构、抗肿瘤作用机制、药效学、毒理学、一般药理学和药动学作一介绍。Salvince that may block tumor cell growth is newly designed to inhibit the action of topoisomerase Ⅱ, an enzyme involved in the relaxation of DNA during the translation and transcription. The preclinical studies demonstrated potent targeted nature of anti-tumor in vivo and in vitro and effectiveness in multiple drug-resistant populations. Salvince was well tolerated. The current review introduces the structural characteristics, the anti-tumor mechanism, the pharmacodynamics, the toxicology, the pharmacology and pharmacokinetics of salvince.

关 键 词：沙尔威辛 拓扑异构酶Ⅱ抑制剂 抗肿瘤作用 临床前研究 

分 类 号：R979.1[医药卫生—药品]